HOME >> MEDICINE >> NEWS
Discovery May Boost Effectiveness Of Chemotherapy

Researchers at the University of Maryland Greenebaum Cancer Center have made a discovery that may explain why some cases of breast cancer and other forms of cancer are resistant to chemotherapy. Their findings, published in the December 22, 1998, issue of Proceedings of the National Academy of Sciences, may lead to better ways to target chemotherapy to individual patients and may open the door to new strategies to reverse resistance to cancer-fighting drugs.

"We have found a cancer resistance protein that rapidly pumps out chemotherapy from a certain line of breast cancer cells," says L. Austin Doyle, M.D., associate professor of medicine at the University of Maryland School of Medicine who is the lead author of the article.

The researchers call the newly-discovered pump Breast Cancer Resistance Protein (BCRP). They found that this protein pumped three common anti-cancer drugs out of cells rapidly, before the drugs could get to the nucleus of the cancer cells and destroy them.

"This is only the fourth molecular drug resistance pump of anti-cancer drugs to be identified, and it is half the size of the other pumps," says Douglas D. Ross, M.D., Ph.D, professor of medicine at the University of Maryland School of Medicine. "We had been looking for years for a way to explain resistance among this group of resistant cancer cells, so this is an important step," adds Dr. Ross, who is a co-author of the article.

The researchers, along with Lynne Abrusso, M.D., Ph.D, assistant professor of pathology at the University of Maryland School of Medicine, studied resistant and non-resistant cancer cells to find genes that were different among the two groups. They used molecular biology techniques to isolate the unique BCRP gene from drug-resistant cancer cells. Then, they tested their theory by changing non-resistant cells into resistant ones by inserting the BCRP gene into them.

"Drug resistance is a big
'"/>

Contact: Ellen Beth Levitt
eblevitt@umms001.ab.umd.edu
410-328-8919
University of Maryland Medical Center
21-Dec-1998


Page: 1 2

Related medicine news :

1. Discovery of pathway in learning impairment caused by liver disease may lead to drug treatment
2. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
3. Discovery of the oldest remains of a woman who died in childbirth
4. Discovery sheds light on how cancer cells grow and divide
5. Discovery changes ideas about damage from strokes
6. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
7. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
8. GlaxoSmithKline Drug Discovery and Development Award 2002
9. Discovery may lead to new HIV drugs, says Jefferson virologist
10. GlaxoSmithKline Drug Discovery and Development Award 2002
11. "Radical" Discovery Advances Medicine and Plastics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Discovery May Boost Effectiveness Chemotherapy

(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
Cached News: